---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Care management intervention strategies"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Care management intervention strategies. Topics: US HAEA Medical Advisory Board guidelines: on-demand medication access, On-demand treatment during long-term prophylaxis: guideline recommendations, Self-administration and home therapy, Monitoring of disease control with validated instruments, and 10 further topics. 14 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### US HAEA Medical Advisory Board guidelines: on-demand medication access

> “Effective treatment of HAE requires that all patients have rapid access to effective on-demand medications.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.4-2"></a>

### On-demand treatment during long-term prophylaxis: guideline recommendations

> “We recommend that patients have access to ODT, even while receiving LTP.”
> “We recommend that patients or their caregivers are advised to always carry enough medication to treat at least 2 HAE attacks.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend supplying all pediatric patients with hereditary angioedema with acute treatment for at least two angioedema attacks even if they are on long‐term prophylaxis.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-3"></a>

### Self-administration and home therapy

> “Self-administration and home therapy are available for all C1-INH products, icatibant, berotralstat, sebetralstat, donidalorsen, garadacimab, and lanadelumab.”
> “We recommend that patients and their caregivers be educated in how to administer ODT, including self-administration with all available formulations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-4"></a>

### Monitoring of disease control with validated instruments

> “We recommend that all patients with HAE use validated instruments to assess disease activity, severity, disease control, treatment efficacy, and QoL, and that they undergo regular reassessments to ensure optimal therapeutic management.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend evaluating efficacy and safety of the long‐term prophylactic agent in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency at least three and six months after initiation, then at least annually.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-5"></a>

### Specialist care and referral centers

> “We recommend that HAE patients be managed by physicians with expertise in the condition, with the support of a referral center.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-6"></a>

### Individualized action plans: guideline recommendations

> “We recommend that all patients have an action plan.”
> “It should include an effective emergency (on-demand) treatment plan, with clear instructions on how to best use medications to treat HAE attacks. Patients should carry on-demand medication and an HAE identification card with instructions on how to manage an HAE attack. Patients on long-term prophylaxis also require an action plan and available therapy for on-demand use.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “We recommend creating an action plan for acute treatment of angioedema attacks in pediatric patients with hereditary angioedema, considering availability of medications and patient/caregiver preferences.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

> “Moreover, identification cards detailing the condition and therapy are essential for proper management of the disease.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-7"></a>

### HAE management plan elements: US HAEA

> “Recent guidelines from the US HAEA Medical Advisory Board call for an HAE Management Plan for every HAE patient.”
> “The patient should know exactly where their medication is kept, how to use it, and who to contact if assistance is required for treatment. Acute treatment medications should be reliably and efficiently accessible to avoid treatment delays.”
> “The US HAEA Medical Advisory Board suggests all patients keep a record of their attacks, noting which medications were used, their response to treatment, and any possible medication side effects.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

> “Because of the rarity of the condition, HAE-specific medications are not readily available in most hospitals and medical facilities, so must be prescribed for individual patients.”
> “Patients should be familiar with refill processes to efficiently replace HAE medications after doses are used.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.4-8"></a>

### Home therapy training: guideline recommendations

> “We recommend that all patients who are provided with on-demand treatment licensed for self-administration should be taught to self-administer.”
> “Home therapy decreases the severity and duration of HAE attacks, reduces morbidity and disability, and can improve quality of life and productivity. In addition, the cost of care is reduced considerably using home and self-therapy.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “All patients with HAE should be trained on self-administration of HAE-specific therapies if they are suitable candidates. If patients cannot self-administer therapy, provisions should be made to ensure timely access to all appropriate therapies.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “We recommend home treatment of angioedema attacks to ensure early treatment in pediatric patients with hereditary angioedema.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-9"></a>

### Education programs and call centers

> “Educational programs focused on the self-administration of on-demand medications, along with national call centers that provide support to patients during acute attacks, have a significant impact on outcomes. Evidence shows that these initiatives can reduce the need for emergency department visits and hospitalizations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-10"></a>

### Comprehensive care and HAE treatment centers

> “We recommend that HAE-specific comprehensive, integrated care is available for all patients.”
> “We recommend that patients are treated by a specialist with specific expertise in managing HAE.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Comprehensive care for all patients with HAE should be provided to optimize treatment and outcomes.”
> “In addition, the ACARE program launched by global HAE patient groups specifies 32 requirements on topics such as infrastructure, management, research, education, and advocacy that must be fulfilled to demonstrate excellence in the management of angioedema”
> “After its implementation in emergency departments, the time to first medication decreased (from 1.3 h to 0.9 h), the diagnosis of airway swelling declined (from 29 to 4%), HAE diagnoses increased (from 10 to 30%), and the use of C1INH more than doubled (from 29 to 61%)”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.4-11"></a>

### Carrying on-demand treatment away from home: patient survey

> “Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home. The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).”

Source: [Betschel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271048/)

<a id="topic-2.2.2.4-12"></a>

### Payer involvement of HAE specialists: International/Canadian guideline

> “Payers must consider the opinion of the HAE specialist when evaluating reimbursement for treatment of patients with HAE, including HAE nC1INH.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.4-13"></a>

### Payer prescriber requirements for on-demand treatments

> “The medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.”

Source: [Cigna Ekterly prior authorization policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0756_coveragepositioncriteria_hereditary_angioedema_ekterly.pdf)

> “Medication must be prescribed by an allergist, immunologist, hematologist, or dermatologist”

Source: [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)

> “Must be prescribed by or under the direction of a HAE specialist. A HAE specialist is defined as an allergist/immunologist who demonstrates clinical expertise in HAE through research, publication, referrals/consults.”

Source: [CountyCare acute HAE products guideline (2026)](https://countycare.com/wp-content/uploads/ECG_5000.CC-for-Acute-Hereditary-Angioedema-Products-ver-Jan-26.pdf)

<a id="topic-2.2.2.4-14"></a>

### Payer benefit channel: pharmacy and medical benefit coverage of on-demand treatments

> “Ekterly is an oral medication and will therefore be covered under the pharmacy benefit”
> “Berinert will be reviewed under the medical benefit when administered by a health care professional. If the member transitions to self-administration, then Berinert can be authorized under the pharmacy benefit.”
> “Firazyr, Sajazir, and icatibant can be self-administered upon recognition of an HAE attack after training under the guidance of a healthcare professional and therefore will be covered under the pharmacy benefit.”

Source: [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
